hotspot -WSS

hotspot

author：fashion 2025-09-28 01:38:34 - browse：54828

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： New details revealed about Purdue's marketing of OxyContin

hotspot

WSS

Vertigo drug brings hope for rare neuron disorder, Niemann

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

A $475,000 price tag for a new cancer drug: crazy or meh?

New details revealed about Purdue's marketing of OxyContin

What we need to know about Arena Bioworks

Vertex non

entertainment

hotspot

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Quicker fix for pulse oximeters urged during FDA public meeting

Medical records are filled with copy

A $475,000 price tag for a new cancer drug: crazy or meh?

Cancer drug shortages should be causing more outrage

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Trump demands the U.S. pay no more for drugs than other countries … again

New Ultima Genomics DNA sequencer can read genome for $100

Medical records are filled with copy

What we need to know about Arena Bioworks

entertainment

Vertigo drug brings hope for rare neuron disorder, Niemann

General Catalyst, Summa Health deal will turn on physician buy

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Quicker fix for pulse oximeters urged during FDA public meeting

ActiGraph execs on goal of drug approvals with digital endpoints

Evacuations in place as 3 wildfires burn in eastern Washington state

hotspot

hotspot

knowledge

hotspot